During the third quarter, we were again able to capture the benefits of AEGON’s strategic priorities, resulting in solid earnings growth, improved profitability of sales, lower expenses and a continued strong capital position. Our franchise remains healthy, as evidenced by the particularly high level of At-Retirement and pension sales. At the same time, we are making essential investments to reshape our businesses in both our established and developing markets to respond effectively to the changing conditions and new realities. Although there are signs of gradually improving market conditions, there remains considerable uncertainty in the general economic environment. Consequently, we believe it is prudent and necessary to maintain a sufficient financial buffer while at the same time adhering to our strict risk and pricing discipline. The steps we are taking across our organization to get closer to our end customers, combined with the strength of our current position, give us full confidence in the prospects for our business going forward.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58637-aegon-quarter-3-results
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange.
With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company’s history of shareholder dividends.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company
http://www.freeinfinitepossibilities.com http://www.freeinfinitepossibilities.com/path-to-success-tips/ Free Infinite Possibilities is about your self development and your awareness of self. Its about developing the most important relationship you will ever have - the relationship with yourself. 5 Success tips on your path to success was formulated so you can start thinking about the framework and the strategies you need to bew the best you that you can be.
http://www.dualfit.com - This 5 step plyometric cardio circuit is great for burning a serious amount of calories and developing explosive muscles!
Check out Steve's site for more workouts like this:
- http://www.pfitpfun.com
- http://www.dobcx.com
Training Style:
Pyometrics, also known as jump training or plyos
Tools:
Dumbbells or Barbell, pull up bar or pull down cable/band, and box or bench
Training Tips:
Plyometric training, primarily used for athletes not only improves strength, power and stamina, it burns a serious amount of calories too. Watch the training video to reference ideal pace and intensity so you get the most out of this workout. In this circuit, each plyometric movement is followed by a strength movement to help improve both conditioning and muscle tone all in one workout. Plyometric exercises should be explosive and powerful. Rest should be limited.
General Mills announces its 150th birthday today with plans for a year-long celebration. To celebrate its impact on a century and a half of food around the world, General Mills will share and highlight nostalgic food memorabilia from its historical archives. And honoring its journey of developing leading brands, life-changing inventions and cultural icons, General Mills is pledging “a future of continued innovation – and striving to help make its communities and the world a better place.”
“Ours is a rich history,” said Ken Powell, chairman and chief executive of General Mills. “Morning, noon and night, for 150 years, General Mills has served the world by making food people love. Today we proudly bring quality foods and leading brands to people in 130 countries around the world – and we’re especially excited about all we will do in our next 150 years.”
To view the multimedia release go to: http://www.multivu.com/players/English/7728051-general-mills-150-th-birthday/
